VivoSeq
Other

Respiratory Distress Syndrome in Premature Infants

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Respiratory Distress Syndrome in Premature Infants is an early-stage landscape with 4 programs across 3 companies. The most active players are Salix, Kaken Pharmaceutical, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Salix

1 program

ApprovedK

Kaken Pharmaceutical

1 program

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)